We identify decreased hepatic igf1 and cyp2r1 expression, key proteins supporting bone formation, and increased hepatic ctgf, fgf21, and anxa2 expression, inhibitors of bone formation, in the setting of MASH and bone loss. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.